7706
A. Tewari et al. / Tetrahedron Letters 45 (2004) 7703–7707
R.; Malet-Martino, M.; Gilard, V. Curr. Drug Metabol.
2000, 1, 271.
12. Uno, H.; Shiraishi, Y.; Shimokawa, K.; Suzuki, H. Chem.
Lett. 1988, 729.
by the Bundesministerium fur Bildung und Forschung
¨
and the state of Mecklenburg–Vorpommern.
13. (a) Avila, D. V.; Ingold, K. U.; Lusztyk, J.; Dolbier, W.
R.; Pan, H.-Q. J. Am. Chem. Soc. 1993, 115, 1577; (b) Wu,
F.-H.; Huang, B.-N.; Lu, L.; Huang, W.-Y. J. Fluorine
Chem. 1996, 80, 91; (c) Kamigata, N.; Fukushima, T.;
Terakawa, Y.; Yoshida, M.; Sawada, H. J. Chem. Soc.,
Perkin Trans. 1 1991, 627.
14. For a review on base-catalyzed hydroamination, see:
Seayad, J.; Tillack, A.; Hartung, C. G.; Beller, M. Adv.
Synth. Catal. 2002, 344, 795.
15. For examples, of base-catalyzed hydroamination of aryl-
alkynes, see: (a) Tzalis, D.; Koradin, C.; Knochel, P.
Tetrahedron Lett. 1999, 40, 6193; (b) Rodriguez, A.;
Koradin, C.; Dohle, W.; Knochel, P. Angew. Chem. 2000,
112, 2607; (c) Angew. Chem., Int. Ed. 2000, 39, 2488; (d)
Lane, C.; Snieckus, V. Synlett 2000, 1294.
References and notes
1. (a) Pelletier, S. W. Chemistry of Alkaloids; Van Nostrand-
Reinhold: New York, 1970; (b) Testa, B.; Salvesen, B. J.
Pharm. Sci. 1980, 69, 497; (c) Laske, R.; Meindl, W.;
Holler, E.; Scho¨nenberger, H. Arch. Pharm. (Weinheim,
Germany) 1989, 322, 297, 847.
2. (a) Glennon, R. A.; Smith, J. D.; Ismaiel, A. M.; El-
Ashmawy, M.; Battaglia, G.; Fisher, J. B. J. Med. Chem.
1991, 34, 1094; (b) Nicols, D. E. J. Med. Chem. 1973, 16,
480; (c) Freifelder, M.; Stone, G. R. J. Am. Chem. Soc.
1958, 80, 5270; (d) Micovic, I. V.; Ivanovic, M. D.; Roglic,
G. M.; Kiricojevic, V. D.; Popovic, J. B. J. Chem. Soc.,
Perkin Trans. 1 1996, 265.
16. X-ray analyses of 1 and 10 clearly show the supposed
configurations of the compounds, but due to the disor-
dered perfluoroalkyl chains the data are not suitable for
publication.
3. (a) Mori, A.; Ishiyama, I.; Akita, H.; Suzuki, K.;
Mitsuoka, T.; Oishi, T. Chem. Pharm. Bull. 1990, 38,
3449; (b) Iwai, I. Chem. Pharm. Bull 1965, 13, 118; (c)
Fujii, M. Chem. Lett. 1992, 6, 933.
17. Baum, K.; Bedford, C. D.; Hunadi, R. J. J. Org. Chem.
1982, 47, 2251.
4. (a) Koziara, A.; Olejniczak, B.; Osowska, K.; Zwierzak, A.
´
´
Synthesis 1982, 918; (b) Barluenga, J.; Jimenez, C.; Najera,
C.; Yus, M. J. Chem. Soc., Perkin Trans. 1 1983, 591; (c)
Griffith, R. C.; Gentile, R. J.; Davidson, T. A.; Scott, F. L.
18. A representative procedure is given for (Z)-N-
(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-1-phenyloct-1-en-2-
yl)morpholine (5): To a stirred solution of morpholine
(0.158g, 1.82mmol) in dry THF, 2equiv of n-BuLi
(3.6mmol, 2.5M in toluene) were added slowly at room
temperature under argon and the reaction mixture was
´
J. Org. Chem. 1979, 44, 3580; (d) Barluenga, J.; Jimenez,
C.; Najera, C.; Yus, M. J. Chem. Soc., Chem. Commun.
´
1981, 670; (e) Larock, R. C. Angew. Chem. 1978, 90, 28; .
Angew. Chem., Int. Ed. Engl. 1978, 17, 27.
stirred for 10min. Then
a
solution of (E)-
5. (a) Kirk-Othmer Encyclopedia of Chemical Technology,
4th ed.; John Wiley and Sons: New York, 1992; p 369; (b)
Bell, F. W.; Cantrell, A. S.; Hoegberg, M.; Jaskunas, S.
R.; Johansson, N. G. J. Med. Chem. 1995, 25, 4929; (c)
Glennon, R. A.; Yousif, M. Y.; Ismaiel, A. M.; El-
Ashmawy, M. B.; Herndon, J. L.; Fischer, J. B.; Server, A.
C.; Burke Howie, K. J. J. Med. Chem. 1991, 34, 3360.
6. (a) Kumar, K.; Michalik, D.; Garcia Castro, I.; Tillack,
A.; Zapf, A.; Arlt, M.; Heinrich, T.; Bo¨ttcher, H.; Beller,
M. Chem. Eur. J. 2004, 10, 746; (b) Beller, M.; Breindl, C.;
Riermeier, T. H.; Eichberger, M.; Trauthwein, H. Angew.
Chem. 1998, 110, 3571; Angew. Chem., Int. Ed. 1998, 38,
3389; (c) Beller, M.; Breindl, C. Tetrahedron 1998, 54,
6359; (d) For amination of styrenes in the presence of
(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-1-iodooct-1-enyl)benzene
(1) (1.0g, 1.82mmol) in THF was added dropwise. The
reaction mixture was allowed to stir at 70°C for 12h. After
cooling to room temperature, the mixture was diluted with
ethyl acetate, washed twice with water, dried over sodium
sulfate, and concentrated in vacuo to give the crude
product, which was purified by column chromatography
1
(ethyl acetate/heptane 20:80) to yield 0.455g (50%) 5. H
=
3
NMR (250MHz, CDCl3): d [ppm] = 2.77 (t, JHH
3
4.6Hz, 4H, 2 morpholine N–CH2), 3.53 (t, JHH = 4.6Hz,
4H, 2 morpholine O–CH2), 6.5 (s, 1H, Ph–CH), 7.26 (m,
5H, aromatic CH). 13C{1H} NMR (126MHz, CDCl3): d
[ppm] = 51.4(2 morpholine N– C2), 66.9 (2 morpholine O–
3
C2), 126.7 (t, JCF = 6.5Hz, Ph–CH), 128.2 (2 aromatic
CH), 128.2 (1 aromatic CH), 129.1 (2 aromatic CH), 134.3
(1 aromatic C), 136.4(t, 2JCF = 21.9Hz, C(NC4H8O)–
´
stoichiometric amounts of base, see: Seijas, J. A.; Vazquez-
´
´
Tato, M. P.; Entenza, C.; Martınez, M. M.; Onega, M. G.;
Veiga, S. Tetrahedron Lett. 1998, 39, 5073.
CF2).
19F{1H}
NMR
(235MHz,
CDCl3):
d
7. Hartung, C. G.; Breindl, C.; Tillack, A.; Beller, M.
Tetrahedron 2000, 56, 5157.
[ppm] = À125.9 (m, CF2), À122.4(m, C F2), À121.5 (m,
3
CF2), À120.5 (m, CF2), À108.8 (t, JFF = 14.5Hz,
8. (a) Muller, T. E.; Beller, M. Chem. Rev. 1998, 98, 675; (b)
¨
3
C(NC4H8O)–CF2), À80.6 (t, JFF = 10Hz, CF3). MS (EI,
For a personal account on hydroamination, see: Beller, M.;
Breindl, C.; Eichberger, M.; Hartung, C. G.; Seayad, J.;
Thiel, O.; Tillack, A.; Trauthwein, H. Synlett 2002, 1579.
9. (a) Maienfisch, P.; Hall, R. G. Chimia 2004, 58, 93; (b)
70eV): m/z (%) 507 (M+, 85), 188 (100).
19. A representative procedure is given for (2-amino-
3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooct-1-yl)benzene (16):
A mixture of (Z)-[2-(N,N-dibenzylamino)-3,3,4,4,5,5,6,6,
7,7,8,8,8-tridecafluorooct-1-en-1-yl]benzene (6) (0.50g,
0.81mmol) and 10mol% Pd (86mg, 10% Pd/C) in THF
(10mL) was stirred under an atmosphere of hydrogen
(1bar) at room temperature for 48h. The mixture was then
filtered through a bed of Celite. The filtrate was concen-
trated in vacuo to get the crude product which was further
purified by column chromatography (ethyl acetate/heptane
30:70) to yield 16 as a white amorphous solid (0.32g, 90%).
Hamprecht, G.; Wurzer, B.; Witschel, M. Chimia 2004, 58,
¨
117; (c) Heinrich, T.; Bo¨ttcher, H.; Bartoszyk, G. D.;
Schwartz, H.; Anzali, S.; Ma¨rz, J.; Greiner, H. E.;
Seyfried, C. A. Chimia 2004, 58, 143; (d) Biomedical
Aspects of Fluorine Chemistry; Filler, R., Kobayashi, Y.,
Eds.; Kodansha and Elsevier: Amsterdam, 1983.
10. Biomedical Frontiers of Fluorine ChemistryACS Sympo-
sium Series; Ojima, I., McCarthy, J. R., Welch, J. T., Eds.;
American Chemical Society: Washington, DC, 1996; Vol.
639.
11. (a) Pandey, S. K.; Gryshuk, A. L.; Graham, A.; Ohkubo,
K.; Fukuzumi, S.; Dobhal, M. P.; Zheng, G.; Ou, Z.;
Zhan, R.; Kadish, K. M.; Oseroff, A.; Ramaprasad, S.;
Pandey, R. K. Tetrahedron 2003, 59, 10059; (b) Martino,
1H NMR (250MHz, CDCl3):
d [ppm] = 2.50 (dd,
3
2JHH = 13.9Hz, JHH = 10.8Hz, 1H, Ph–CHa), 3.10 (d,
2JHH = 14.0Hz, 1H, Ph–CHb), 3.45–3.59 (m, 1H, CH–
NH2), 7.18–7.28 (m, 5H, 5 aromatic H). 13C{1H} NMR
(126MHz, CDCl3): d [ppm] = 35.8 (Ph–C2), 54.5 (t,